A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Ipafricept (Primary)
  • Indications Fibroma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 16 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 14 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top